By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



3260 Bayshore Boulevard

Brisbane  California  94005  U.S.A.
Phone: 415-287-2300 Fax: 415-287-2450


CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. CareDx offers AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate to severe acute cellular rejection. CareDx is developing additional products for transplant monitoring using a variety of technologies, including AlloSure®, a proprietary next-generation sequencing–based test to detect donor-derived cell-free DNA after transplantation.

CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP® is a set of HLA typing used prior to hematopoietic stem cell/bone marrow transplantation and organ transplantation. XM-ONE® is the first standardized test that quickly identifies a patient’s antigens against HLA Class I, Class II or antibodies against a donor’s endothelium. For more information, please visit:

Key Statistics

Ownership: Public

Web Site: CareDx
Symbol: CDNA


Company News
CareDx (CDNA) Release: 100,000th AlloMap Result Provided To Heart Transplant Patients 7/13/2017 8:15:43 AM
CareDx (CDNA) Reports First Quarter 2017 Financial Results 6/9/2017 8:04:45 AM
CareDx (CDNA) Activities At European Federation of Immunogenetics Congress 5/30/2017 10:42:39 AM
CareDx (CDNA) Reports Preliminary First Quarter 2017 Financial Results 5/23/2017 11:23:15 AM
CareDx (CDNA) Announces Receipt Of Expected Letter From Nasdaq 5/23/2017 11:22:11 AM
CareDx (CDNA) To Announce First Quarter 2017 Preliminary Financial Results On May 22, 2017 5/19/2017 7:40:58 AM
CareDx (CDNA) Reports Fourth Quarter And Full Year 2016 Financial Results 4/24/2017 11:47:04 AM
CareDx (CDNA) Announces Receipt Of Expected Letter From Nasdaq 4/24/2017 11:45:54 AM
CareDx (CDNA) Appoints Michael Bell As Chief Financial Officer 4/24/2017 11:44:52 AM
Horizon Discovery Ltd. And CareDx (CDNA) Enter Into OEM Agreement For Routine Inclusion Of Cell-Free DNA Reference Standards In Transplant Testing 11/9/2016 10:03:21 AM